Diagnosis and therapy of cancer (i.e. leukemia and prostate) tailored for the patient subgroup re-sistant to TRAIL induced apopt

TRAIL has recently emerged as a novel potential anticancer agent. However, cancer cells are in specific patients resistant to TRAIL induced apoptosis. Therefore the efficacy of chemotherapy for treatment of CLL, MCL, HNSCC, bladder or prostate carci-noma is often limited due to resistance to TRAIL induced apoptosis. The technology provides a method for identification of these non-responders. Moreover, a polynucleotide encoding the modified TRAIL can serve as drug against such cancer diseases of this specific patient subgroup.

Further Information: PDF

Deutsches Krebsforschungszentrum DKfZ
Phone: +49-6221-422958

Contact
Regina Otto

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

High-energy-density aqueous battery based on halogen multi-electron transfer

Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…

First-ever combined heart pump and pig kidney transplant

…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…

Biophysics: Testing how well biomarkers work

LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…

Partners & Sponsors